ProjectKOMET Studie

Basic data

Title:
KOMET Studie
Duration:
12/10/2021 to 31/10/2024
Abstract / short description:
Klinische Prüfung - KOMET Studie
A Phase III. Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NFI who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET).

Involved staff

Managers

Department of Neurosurgery
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine

Other staff

Department of Neurosurgery
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen

Local organizational units

Department of Neurosurgery and Neurotechnology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Wedel, Schleswig-Holstein, Germany
Help

will be deleted permanently. This cannot be undone.